Clinical evaluation of efficacy and safety of CLARITH Tablets 200 mg (800mg/day) against community acquired bacterial pneumonia and mycoplasma pneumonia. - Clinical evaluation of CLARITH Tablets 200 mg (800mg/day) against community acquired bacterial pneumonia and mycoplasma pneumonia.

Organization of Clinical Trials for Respiratory and Infectious Disease0 sites24 target enrollmentOctober 29, 2012

Overview

Phase: 未知
Intervention: Not specified
Conditions: community acquired bacterial pneumonia and mycoplasma pneumonia
Sponsor: Organization of Clinical Trials for Respiratory and Infectious Disease
Enrollment: 24
Status: Completed
Last Updated: 2 years ago

No summary available.

Registry

who.int

Start Date

October 29, 2012

End Date

March 31, 2013

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Organization of Clinical Trials for Respiratory and Infectious Disease

•1\)Patients with known hypersensitivity to clarithromycin or any other component of the product. 2\)Patients receiving treatment with pimozide, ergotamine(or its derivatives), or tadalafil/ADCIRCA. 3\)Patients under 20 years old. 4\)Patients with hypersensitivity to any other antibiotics. 5\)Patients with hepatic dysfunction, renal impairment, cardiac disorder, or other severe complication which inadequate this study. 6\)Women known pregnant, lactation or suspected to be pregnant. 7\)Patients who are regarded as inadequate subject by physician in charge (\*) \*Posible to enter the patients who treat low\-dose long\-time macrolides therapy(200mg) when increase the dosage(800mg). \*Posible to enter the patients who previously treat 400mg of clarithromycin if increase the dosage(800mg).